Inhaled zanamivir was noninferior to oral oseltamivir in preventing severe influenza-related outcomes in a study of more than 865,000 outpatients in Taiwan, researchers reported in Clinical Infectious Diseases.
“Individual patient data meta-analyses of randomized controlled trials show that early oseltamivir treatment for influenza cut risk of pneumonia and hospitalization by 44% and 63%, respectively,” Chia-Ping Su, PhD, medical officer at the Taiwan Centers for Disease Control, and colleagues wrote. “However, data are lacking for inhaled zanamivir on its effectiveness to